Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Science (New York, N.Y.)
|
January 31, 2009
Mechanically activated integrin switch controls alpha5beta1 function
Julie C Friedland, Mark H Lee, David Boettiger
Journal of Neurotrauma
|
July 16, 2004
Traumatic brain injury elevates glycogen and induces tolerance to ischemia in rat brain
Tatsuo Otori, Julie C Friedland, Grant Sinson, et al.
Journal of Cell Science
|
October 4, 2007
alpha6beta4 integrin activates Rac-dependent p21-activated kinase 1 to drive NF-kappaB-dependent resistance to apoptosis in 3D mammary acini
Julie C Friedland, Johnathon N Lakins, Marcelo G Kazanietz, et al.
Investigational New Drugs
|
May 21, 2013
Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes
Julie C Friedland, Donald L Smith, Jim Sang, et al.
Molecular Cancer Therapeutics
|
September 27, 2012
Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib
Jaime Acquaviva, Donald L Smith, Jim Sang, et al.
International Journal of Oncology
|
November 16, 2012
Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression
Suqin He, Chaohua Zhang, Ayesha A Shafi, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 19, 2004
Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors
John F Cryan, Olivia F O'Leary, Sung-Ha Jin, et al.
Melanoma Research
|
May 13, 2022
Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma
Zachary Wolfe, Julie C Friedland, Sarah Ginn, et al.
Cancer Discovery
|
March 28, 2013
Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer
Jim Sang, Jaime Acquaviva, Julie C Friedland, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Science (New York, N.Y.)
|
January 31, 2009
Mechanically activated integrin switch controls alpha5beta1 function
Julie C Friedland, Mark H Lee, David Boettiger
Journal of Neurotrauma
|
July 16, 2004
Traumatic brain injury elevates glycogen and induces tolerance to ischemia in rat brain
Tatsuo Otori, Julie C Friedland, Grant Sinson, et al.
Journal of Cell Science
|
October 4, 2007
alpha6beta4 integrin activates Rac-dependent p21-activated kinase 1 to drive NF-kappaB-dependent resistance to apoptosis in 3D mammary acini
Julie C Friedland, Johnathon N Lakins, Marcelo G Kazanietz, et al.
Investigational New Drugs
|
May 21, 2013
Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes
Julie C Friedland, Donald L Smith, Jim Sang, et al.
Molecular Cancer Therapeutics
|
September 27, 2012
Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib
Jaime Acquaviva, Donald L Smith, Jim Sang, et al.
International Journal of Oncology
|
November 16, 2012
Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression
Suqin He, Chaohua Zhang, Ayesha A Shafi, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 19, 2004
Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors
John F Cryan, Olivia F O'Leary, Sung-Ha Jin, et al.
Melanoma Research
|
May 13, 2022
Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma
Zachary Wolfe, Julie C Friedland, Sarah Ginn, et al.
Cancer Discovery
|
March 28, 2013
Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer
Jim Sang, Jaime Acquaviva, Julie C Friedland, et al.
Page
of 1